EP0503050A4 - Hybrid growth factors - Google Patents

Hybrid growth factors

Info

Publication number
EP0503050A4
EP0503050A4 EP19910918221 EP91918221A EP0503050A4 EP 0503050 A4 EP0503050 A4 EP 0503050A4 EP 19910918221 EP19910918221 EP 19910918221 EP 91918221 A EP91918221 A EP 91918221A EP 0503050 A4 EP0503050 A4 EP 0503050A4
Authority
EP
European Patent Office
Prior art keywords
growth factors
hybrid growth
hybrid
factors
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910918221
Other versions
EP0503050A1 (en
Inventor
Jonathan I Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of EP0503050A1 publication Critical patent/EP0503050A1/en
Publication of EP0503050A4 publication Critical patent/EP0503050A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
EP19910918221 1990-09-28 1991-09-26 Hybrid growth factors Withdrawn EP0503050A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58995890A 1990-09-28 1990-09-28
US589958 1990-09-28

Publications (2)

Publication Number Publication Date
EP0503050A1 EP0503050A1 (en) 1992-09-16
EP0503050A4 true EP0503050A4 (en) 1994-07-06

Family

ID=24360286

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910918221 Withdrawn EP0503050A4 (en) 1990-09-28 1991-09-26 Hybrid growth factors

Country Status (8)

Country Link
EP (1) EP0503050A4 (en)
JP (1) JPH05502463A (en)
AU (2) AU8735991A (en)
CA (1) CA2069746A1 (en)
IE (1) IE913426A1 (en)
PT (1) PT99107A (en)
WO (1) WO1992006116A1 (en)
ZA (1) ZA917766B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
ES2118756T5 (en) * 1990-08-29 2004-01-16 Genetics Institute, Llc HEMATOPOYESIS STIMULATORS OF MULTIPLE DOMAINS.
DE69333243T2 (en) * 1992-11-24 2004-08-19 G.D. Searle & Co., Chicago MUTTED INTERLEUKIN-3 (IL-3) POLYPEPTIDES
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
WO1995028427A1 (en) * 1994-04-15 1995-10-26 Imclone Systems Incorporated Chimeric interleukin-3/mutein interleukin-6 lymphokine
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
ITFI940106A1 (en) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa HYBRID MOLECULE OF GM-CSF-L-EPO OR EPO-L-GM-CSF FORMULA FOR ERYTHROPOIETIC STIMULATION
IT1271688B (en) * 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa HYBRID MOLECULES FOR ANTI-CANCER TREATMENT THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
WO1996034016A1 (en) * 1995-04-26 1996-10-31 Kyowa Hakko Kogyo Co., Ltd. Novel polypeptides
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
CA2265989C (en) * 1996-09-20 2010-11-02 Ortho-Mcneil Pharmaceutical, Inc. Methods for in vitro determination of erythropoietin bioactivity
IL129565A0 (en) * 1996-10-25 2000-02-29 Searle & Co Multi-functional chimeric hematopoietic receptor agonists
AU721196B2 (en) * 1996-10-25 2000-06-29 G.D. Searle & Co. Circularly permuted erythropoietin receptor agonists
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
EP0902085B1 (en) * 1997-09-01 2003-12-03 Aventis Pharma Deutschland GmbH Recombinant human erythropoietin with advantageous glycosylation profile
WO1999041382A2 (en) * 1998-02-17 1999-08-19 Hyseq, Inc. A novel interleukin-3 and uses thereof
BR9917606A (en) * 1998-11-06 2002-12-31 Bio Sidus S A Procedure for the purification of recombinant human erythropoietin from cell culture supernatants and recombinant human erythropoietin obtained with such procedure
WO2001087329A1 (en) 2000-05-15 2001-11-22 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivate
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
JP5840148B2 (en) 2010-03-04 2016-01-06 フェニックス インク． Method for producing soluble recombinant interferon protein without denaturation
NZ603033A (en) 2010-04-01 2014-06-27 Pfenex Inc Methods for g-csf production in a pseudomonas host cell
CN104487475B (en) 2012-07-31 2017-04-12 旭化成株式会社 Epoxy resin composition, epoxy resin, and cured article
LT6161B (en) 2013-09-27 2015-06-25 Uab Profarma Fused proteins of granulocyte colony-stimulating factor with other partners of growh factor, preferably with stem cell factor, and method of preparation thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001039A1 (en) * 1988-07-20 1990-02-08 Immunex Corporation Nonglycosylated human interleukin-3 compositions
WO1990012874A2 (en) * 1989-04-21 1990-11-01 Genetics Institute, Inc. Cysteine added variants of polypeptides and chemical modifications thereof
WO1991002754A1 (en) * 1989-08-22 1991-03-07 Immunex Corporation Fusion proteins comprising gm-csf and il-3
WO1991007988A1 (en) * 1989-12-01 1991-06-13 Amgen Inc. Megakaryocyte production
WO1992004455A1 (en) * 1990-08-29 1992-03-19 Genetics Institute, Inc. Multidomain hematopoiesis stimulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2534222B2 (en) * 1982-05-12 1996-09-11 プレジデント アンド フエロウズ オブ ハ−バ−ド カレツジ Fusion gene for mixed protein production
US4935352A (en) * 1985-10-21 1990-06-19 Takeda Chemical Industries, Ltd. Expression vector for animal cell line and use thereof
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
NZ221298A (en) * 1986-08-01 1990-07-26 Commw Scient Ind Res Org A recombinant vaccine comprising an antigenic polypeptide component together with a lymphokine component
CA2035868A1 (en) * 1989-07-06 1991-01-07 Richard C. Svrluga Hybrid molecules
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001039A1 (en) * 1988-07-20 1990-02-08 Immunex Corporation Nonglycosylated human interleukin-3 compositions
WO1990012874A2 (en) * 1989-04-21 1990-11-01 Genetics Institute, Inc. Cysteine added variants of polypeptides and chemical modifications thereof
WO1991002754A1 (en) * 1989-08-22 1991-03-07 Immunex Corporation Fusion proteins comprising gm-csf and il-3
WO1991007988A1 (en) * 1989-12-01 1991-06-13 Amgen Inc. Megakaryocyte production
WO1992004455A1 (en) * 1990-08-29 1992-03-19 Genetics Institute, Inc. Multidomain hematopoiesis stimulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S. TANIKAWA ET AL: "Effects of recombinant granulocyte colony-stimulatinfg-factor (rG-CSF) and recombinant granulocyte-macrophage colony-stimulating-factor (rGM-CSF) on acute radiation hematopoietic injury in mice", EXPERIMENTAL HEMATOLOGY, vol. 17, 1989, pages 883 - 888 *
See also references of WO9206116A1 *

Also Published As

Publication number Publication date
CA2069746A1 (en) 1992-03-29
WO1992006116A1 (en) 1992-04-16
JPH05502463A (en) 1993-04-28
AU8735991A (en) 1992-04-28
EP0503050A1 (en) 1992-09-16
PT99107A (en) 1992-08-31
ZA917766B (en) 1993-03-29
IE913426A1 (en) 1992-04-08
AU1157695A (en) 1995-04-13

Similar Documents

Publication Publication Date Title
EP0503050A4 (en) Hybrid growth factors
IL103684A0 (en) Novel hybrid transforming growth factors
EP0728142A4 (en) Novel antler-derived bone growth factors
IL96048A0 (en) Crystalline polyimidesiloxanes
IL96902A0 (en) T cell growth factor
GB2248016B (en) Day surgery trolley
GB9004679D0 (en) Semiconductor growth
GB9225928D0 (en) Growth factor
GB9009540D0 (en) Floral arrangement
GB9016571D0 (en) Trolley aid
GB9006147D0 (en) Polypropylene
AU168P (en) KEINOUMI Rosa hybrid
AU197P (en) COCDESTIN Rosa hybrid
AU76P (en) MEIGOVIN Rosa hybrid
AU75P (en) MEIBARKE Rosa hybrid
AU326P (en) Auscot Rosa hybrid
AU325P (en) Ausblush Rosa hybrid
AU239P (en) NOATRAUM Rosa hybrid
AU96P (en) TANSCHAUBUD Rosa hybrid
AU103P (en) STEBIGPU Rosa hybrid
AU81P (en) MEIXERUL Rosa hybrid
AU104P (en) AROBIPY Rosa hybrid
AU77P (en) SCHOBITET Rosa hybrid
AU171P (en) KEITAIBU Rosa hybrid
AU170P (en) MEIXTRAFLO Rosa hybrid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920430

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RHK1 Main classification (correction)

Ipc: C12N 15/62

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19951123

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960405